Octreotide

Acromegaly

Octreotide is used to lower the levels of growth hormone and insulin-like growth factor-1 (IGF-1) in adults with acromegaly. This condition occurs when the body produces too much growth hormone, leading to the abnormal growth of bones and tissues. It is generally prescribed for patients who have had an inadequate response to or are not candidates for other treatments like surgery or radiation.

Carcinoid Tumors

This medication is used to manage symptoms associated with metastatic carcinoid tumors. Specifically, it helps control:

• Severe diarrhea
• Sudden skin flushing

Vasoactive Intestinal Peptide Tumors (VIPomas)

Octreotide is used to treat the profuse, watery diarrhea associated with VIPomas. These are rare tumors that secrete vasoactive intestinal peptide, a substance that causes the intestines to release large amounts of water and salts.

Mechanism of Action

Octreotide is classified as a somatostatin analog. It functions similarly to somatostatin, a hormone naturally produced by the body that acts as a regulator to inhibit the release of other hormones and secretory proteins.

Hormone Regulation

In patients with acromegaly, octreotide works by reducing the production of growth hormone and insulin-like growth factor 1 (IGF-1). By lowering these levels, the medication helps control the excessive growth of bones and organs associated with the condition.

Symptom Management

Octreotide is also used to manage symptoms caused by certain types of tumors in the gastrointestinal tract or pancreas. It works by suppressing the release of various substances into the bloodstream, including:

• Serotonin: Reducing this chemical helps control flushing and diarrhea associated with carcinoid tumors.
• Vasoactive intestinal peptide (VIP): Blocking this peptide helps reduce the severe watery diarrhea caused by VIPomas.
• Digestive enzymes and fluids: The medication slows down the movement of the digestive tract and reduces the secretion of water and electrolytes into the intestines.

Common Side Effects

Many people using octreotide experience digestive symptoms. These often improve over time as the body adjusts to the medication. Common side effects include:

• Diarrhea or oily stools
• Stomach pain, gas, or bloating
• Nausea
• Constipation
• Headache or dizziness
• Fatigue
• Pain, itching, or redness at the injection site

Serious Side Effects

Some side effects can be serious. Seek medical attention right away if you experience:

• Severe pain in the upper right stomach or between the shoulder blades, which may indicate gallstones
• A very slow or irregular heartbeat
• Signs of underactive thyroid, such as unexplained weight gain, dry skin, or sensitivity to cold
• Significant changes in blood sugar, including extreme thirst, frequent urination, or sudden shakiness and sweating
• Severe abdominal pain that spreads to the back, which may be a sign of pancreatitis

Gallbladder Complications

Octreotide can reduce gallbladder movement and bile flow, which frequently leads to the development of gallstones or gallbladder sludge. Healthcare providers may perform ultrasound exams before and during treatment to monitor for these issues.

Blood Sugar Changes

This medication influences the hormones that regulate blood sugar. It can cause either high blood sugar (hyperglycemia) or low blood sugar (hypoglycemia). People with diabetes may need to monitor their glucose levels more frequently and adjust their medications as directed by a professional.

Heart and Rhythm Effects

Slow heart rate (bradycardia) and other conduction abnormalities have been observed in patients using octreotide. Caution is typically used in patients with pre-existing heart conditions.

Thyroid and Nutritional Monitoring

Long-term use may suppress thyroid function, potentially leading to hypothyroidism. Additionally, the drug can interfere with the absorption of fats and vitamin B12, which may require monitoring of nutritional levels.

Organ Impairment

Individuals with severe kidney disease or liver cirrhosis may process the drug differently. Dosage adjustments are often necessary for those with impaired renal or hepatic function to avoid excessive levels of the medication in the blood.

Hypersensitivity

Severe allergic reactions, including anaphylaxis, have been reported. Immediate medical attention is necessary if signs of a serious reaction occur.

Pregnancy

There are no adequate and well-controlled studies of octreotide use in pregnant women. While animal studies have not shown evidence of harm to the fetus at doses much higher than those used in humans, animal research does not always predict human response. Therefore, octreotide is generally only used during pregnancy if the potential benefit to the mother outweighs the potential risk to the fetus.

In some cases, octreotide may restore fertility in women with acromegaly by normalizing growth hormone and insulin-like growth factor-1 (IGF-1) levels. Women of childbearing potential should discuss the use of effective contraception with their healthcare provider while receiving treatment to avoid unintended pregnancy.

Breastfeeding

It is not known whether octreotide is excreted in human breast milk. Because many drugs are passed into milk and the effects on a nursing infant are unknown, caution is advised. Healthcare providers typically evaluate the importance of the medication to the mother and the potential risks to the infant when deciding whether to continue breastfeeding during treatment.

Injection Formulations

Octreotide is frequently administered by injection. There are two primary types of injectable formulations:

• Immediate-release injection: This form is typically injected under the skin (subcutaneously) or into a vein (intravenously). It is available in single-dose ampules and multi-dose vials.
• Long-acting (extended-release) injection: This form is a suspension designed to release the medication slowly over time. It is administered by a healthcare professional as an injection into the muscle (intramuscularly), usually in the buttock.

Oral Formulation

Octreotide is also available as a delayed-release oral capsule. This formulation is typically taken twice daily on an empty stomach.

FDA Approval Status

Octreotide was first approved by the U.S. Food and Drug Administration (FDA) in 1988 as an injectable treatment. Over time, the FDA has approved multiple formulations, including immediate-release injections, long-acting suspensions, and oral capsules.

Approved Indications

The FDA has approved octreotide for the following conditions:

• Acromegaly: Used to lower levels of growth hormone and IGF-1 in adults who have had an inadequate response to or are not candidates for surgery or radiation.
• Carcinoid Tumors: Used to treat severe diarrhea and flushing associated with metastatic carcinoid tumors.
• Vasoactive Intestinal Peptide Tumors (VIPomas): Used to treat profuse watery diarrhea associated with these specific tumors.

Regulatory Requirements

Octreotide is a prescription-only medication. There are currently no boxed warnings or Risk Evaluation and Mitigation Strategies (REMS) required by the FDA for this drug. Healthcare providers monitor patients for potential side effects, such as gallbladder issues or changes in thyroid or blood sugar levels, as part of standard clinical practice.

Factors Influencing Cost

The price of octreotide treatment depends on several variables related to the specific product and how it is administered:

• Formulation: Octreotide is available as an immediate-release injection, a long-acting injection (LAR), and an oral capsule. Generic immediate-release injections are generally less expensive than brand-name products or specialized long-acting and oral formulations.
• Generic Availability: While generic versions of the immediate-release injection exist, newer formulations like oral capsules or specific long-acting pens may only be available as brand-name medications, which typically carry a higher price.
• Administration Fees: Long-acting injections must be administered by a healthcare professional in a clinical setting. This may result in additional costs for the office visit and the administration procedure, which are separate from the cost of the medication itself.

Insurance and Financial Assistance

Insurance coverage for octreotide depends on the specific plan and whether the medication is processed through a pharmacy benefit or a medical benefit. Because octreotide is often used for chronic conditions, long-term costs can be substantial. Many manufacturers of brand-name octreotide products offer patient assistance programs or co-pay savings cards to help eligible patients manage out-of-pocket expenses. Patients are encouraged to check with their insurance provider and pharmacy to determine their specific coverage and potential for financial support.